Corcept Therapeutics Enters Material Definitive Agreement
Ticker: CORT · Form: 8-K · Filed: Apr 17, 2024 · CIK: 1088856
Sentiment: neutral
Topics: material-agreement, financial-obligation
TL;DR
Corcept just signed a big deal, details to come.
AI Summary
Corcept Therapeutics Inc. entered into a material definitive agreement on April 12, 2024. This agreement involves a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. Further details regarding the nature and terms of this agreement are expected to be disclosed.
Why It Matters
This filing indicates a significant new financial commitment or arrangement for Corcept Therapeutics, which could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement and financial obligation, the specifics of which are not yet fully disclosed, creating uncertainty.
Key Players & Entities
- Corcept Therapeutics Incorporated (company) — Registrant
- April 12, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 149 Commonwealth Drive, Menlo Park, CA 94025 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Corcept Therapeutics?
The filing states that Corcept Therapeutics entered into a material definitive agreement, which involves a direct financial obligation or an obligation under an off-balance sheet arrangement. Specific details of the agreement are not provided in this initial report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on April 12, 2024.
What is Corcept Therapeutics' principal executive office address?
Corcept Therapeutics' principal executive office is located at 149 Commonwealth Drive, Menlo Park, CA 94025.
Under which section of the Securities Exchange Act is this 8-K filed?
This 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
What is the SIC code for Corcept Therapeutics?
The Standard Industrial Classification (SIC) code for Corcept Therapeutics is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 631 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-04-17 06:05:32
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value CORT The Nasdaq Stock Mar
- $1.4 million — ted to pay a base rent of an average of $1.4 million annually and a Shared Amenities Space b
- $240,000 — nities Space base rent of an average of $240,000 annually over the term of the lease. Pu
Filing Documents
- d827422d8k.htm (8-K) — 26KB
- 0001193125-24-098492.txt ( ) — 141KB
- cort-20240412.xsd (EX-101.SCH) — 3KB
- cort-20240412_lab.xml (EX-101.LAB) — 17KB
- cort-20240412_pre.xml (EX-101.PRE) — 11KB
- d827422d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CORCEPT THERAPEUTICS INCORPORATED Date: April 17, 2024 By: /s/ Atabak Mokari Name: Atabak Mokari Title: Chief Financial Officer